Technologies & Start-ups
The Business Development Team is always working on new and exciting research. A selection of current projects is detailed below. Contact us to find out more.
Hatchtech Pty Ltd
Low Toxicity Insecticides. Hatchtech is a start-up company that builds on the expertise of staff at the University of Melbourne's Centre for Animal Biotechnology to develop a new generation of low-toxicity ovacides for human parasites.
View more information about Hatchtech Pty Ltd
Velacor Therapeutics Pty Limited
A novel approach to cancer treatment. Velacor is developing a novel treatment for prostate cancer through inhibition of the protein kinase Akt pathway.
View more information about Velacor Therapeuticcs Pty Limited
New drugs for Parkinson's disease
ProCypra has developed novel class of compounds that have the potential to cure Parkinson's Disease and other motor neurone degenerative disorders.
Contact Sean Lumb for more information on 8344 3199
Diagnostic for Multiple Sclerosis
The discovery of novel loci and single nucleotide polymorphisms associated with multiple sclerosis gives rise to new targets for drug therapies and opens the door for stratification of MS patients in clinical drug trials, thus leading to more effective drugs and better quality of life for MS sufferers.
Contact Dr Andrew Leech for more information on 8344 3197
Novel Imaging Mode –extending the limits of microscopy
A technology that will allow imaging of processes at the nano-scale, which is a significant leap forward from existing techniques that can only provide structural information at the nano-scale. The technology will be implemented as an alternative imaging system for an AFM, and has generated early interest from leading vendors.
Contact Richard Day for more information on 8344 3066
Fully synthetic TLR - targeting immunomodulator
Lipopeptide capable of complexing charged antigens and eliciting strong immune responses in vivo. This technology has broad applications in the field of prophylactic and therapeutic vaccine (including DNA vaccine), ex vivo DC therapy and/or supplementing existing adjuvant technologies.
Contact Christophe DeMaison for more information on 8344 3086
Carbon Liability Optimisation Software – assisting companies to deal with the CPRS
Software that allows organisations to optimise their investment planning, to maximise profit whilst minimising their emissions liability under the impending CPRS.
Contact Richard Day for more information on 8344 3066
Fully synthetic TLR - targeting immunomodulator
Lipopeptide capable of complexing charged antigens and eliciting strong immune responses in vivo. This technology has broad applications in the field of prophylactic and therapeutic vaccine (including DNA vaccine), ex vivo DC therapy and/or supplementing existing adjuvant technologies.
Contact Christophe DeMaison for more information on 8344 3086
Speeding up the Internet
A new modulation method for the encoding of data sent on optical fibre telecommunication networks. The fundamental advantages of this method may provide the basis for future generations of optical data transmission.
Contact Richard Day for more information on 8344 3066
Efficient, easily implemented database indexing technique for spatial data
A sophisticated indexing technique which enables the mapping of multi-dimensional spatial data to a 1 dimensional index structure, overcoming the challenges associated with current best alternative (R+ tree)..
Contact Ivan Mellado for more information on 8344 3192
Quantum Dot Light Emitting Diodes (QD-LED)
A sol-gel based process is employed to produce an all inorganic QD-LED that consumes 1-2 orders magnitude less power to generate equivalent luminance of an incandescent or fluorescent light bulb.
Contact Sabina Zahirovic for more information on 8344 3067
Marine anti-fouling
Non-toxic, low-cost coating that prevents biofouling of ships' hulls and water treatment equipment. The coating works by camouflaging the surface to look like water, thereby preventing bacteria and diatoms from adhering.
Contact Greg Pullen for more information on 8344 3191
OPAL Therapeutics Pty Limited
Novel treatment for HIV & Hepatitis C (HCV). OPAL Therapeutics is investigating a novel, simple and easy to administer vaccine for HIV and HCV.
View more information about OPAL Therapeutics Pty Limited
Uniseed Portfolio (Melbourne-based)
For further information on the following projects, please contact the Uniseed Investment Committee Project Manager or the Uniseed Regional Director.
To discuss any of these UniSeed investments, please contact:
John Kurek
Melbourne Investment Manager
Uniseed
211 Grattan Street
Carlton Victoria. 303
Australia
Email: j.kurek@uniseed.com
Phone: +61 3 8344 3193
Fax: +61 3 9347 5888
Peter Devine
Chief Executive Officer
Uniseed Management Pty Ltd
Level 7, GP South Building
Staff House Road
St. Lucia QLD 407
Email: p.devine@uniseed com
Phone: +61 7 3365 6937
Fax: +61 7 3365 4433